Current Report Filing (8-k)
February 16 2018 - 12:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report: February 13, 2018 (Date of earliest event reported)
BIO-RAD
LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Commission
File Number:
1-7928
|
|
|
Delaware
|
|
94-1381833
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
1000 Alfred Nobel Dr.
Hercules, California 94547
(Address of principal executive offices, including zip code)
(510)
724-7000
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
ITEM 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On February 13, 2018, John Goetz, the Executive Vice President, Chief Operating Officer of
Bio-Rad
Laboratories,
Inc. (the Company) and a named executive officer of the Company, informed the Company of his intention to retire and resign from his position at the Company, to be effective March 30, 2018. The Company is undertaking a search for a
successor. Mr. Goetz has indicated that if a successor has not been named by March 30, 2018, he will remain available for consultation after his employment ends under terms to be discussed with the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
BIO-RAD LABORATORIES, INC.
|
|
|
|
|
Date: February 16, 2018
|
|
|
|
By:
|
|
/s/ Timothy S. Ernst
|
|
|
|
|
|
|
Timothy S. Ernst
|
|
|
|
|
|
|
Executive Vice President, General Counsel and Secretary
|
Bio Rad Laboratories (NYSE:BIO.B)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Rad Laboratories (NYSE:BIO.B)
Historical Stock Chart
From Apr 2023 to Apr 2024